815 results on '"Severens, Johan L."'
Search Results
2. Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report
3. Cost-Effectiveness Analysis in Telehealth: A Comparison between Home Telemonitoring, Nurse Telephone Support, and Usual Care in Chronic Heart Failure Management
4. Adverse events associated with bone-conduction and middle-ear implants: a systematic review
5. TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility
6. Health care input constraints and cost effectiveness analysis decision rules
7. Impact of hospitalisation on health-related quality of life in patients with chronic heart failure
8. Exploring the Cost-Effectiveness of Mechanical Thrombectomy Beyond 6 Hours Following Advanced Imaging in the United Kingdom
9. The Association Between Physical Distancing Behaviors to Avoid COVID-19 and Health-Related Quality of Life in Immunocompromised and Nonimmunocompromised Individuals: Patient-Informed Protocol for the Observational, Cross-Sectional EAGLE Study.
10. Costs of Hospital Stay in Specialized Diabetic Foot Department in Russia
11. A reference case for economic evaluations in osteoarthritis: An expert consensus article from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
12. The Effect of Presenting Information about Invasive Follow-Up Testing on Individuals’ Noninvasive Colorectal Cancer Screening Participation Decision: Results from a Discrete Choice Experiment
13. Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model
14. A review of economic evaluations of behavior change interventions: setting an agenda for research methods and practice
15. Diagnosing Alzheimer's disease: A systematic review of economic evaluations
16. Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
17. Response to Letter to the Editor Regarding “Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal”
18. Health economics in the field of osteoarthritis: An Expert's consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO)
19. Cost for Treatment of Chronic Lymphocytic Leukemia in Specialized Institutions of Ukraine
20. The Cloudy Crystal Ball of Cost-Effectiveness Studies
21. Lenalidomide for the Treatment of Low- or Intermediate-1-Risk Myelodysplastic Syndromes Associated with Deletion 5q Cytogenetic Abnormality: An Evidence Review of the NICE Submission from Celgene
22. Productivity cost calculations in health economic evaluations: Correcting for compensation mechanisms and multiplier effects
23. Exploring non-health outcomes of health promotion: The perspective of participants in a lifestyle behaviour change intervention
24. Reviewing the Cost-Effectiveness of Endocrine Early Breast Cancer Therapies: Influence of Differences in Modeling Methods on Outcomes
25. Development of a Composite Questionnaire, the Valuation of Lost Productivity, to Value Productivity Losses: Application in Rheumatoid Arthritis
26. Health-related quality of life after fast-track treatment results from a randomized controlled clinical equivalence trial
27. Modeling the Value for Money of Changing Clinical Practice Change: A Stochastic Application in Diabetes Care
28. Considered judgement in evidence-based guideline development
29. Exposure to Tuberculosis among Newborns in a Nursery: Decision Analysis for Initiation of Prophylaxis
30. Patients’ preferences and economic considerations play an important role in treatment decisions: a discrete choice experiment among rheumatologists
31. Modelling Outcomes of Complex Treatment Strategies Following a Clinical Guideline for Treatment Decisions in Patients with Rheumatoid Arthritis
32. Challenges in Modelling the Cost Effectiveness of Various Interventions for Cardiovascular Disease
33. What Do International Pharmacoeconomic Guidelines Say about Economic Data Transferability?
34. The Transferability of Valuing Lost Productivity across Jurisdictions. Differences between National Pharmacoeconomic Guidelines
35. Transferability of Model-Based Economic Evaluations: The Case of Trastuzumab for the Adjuvant Treatment of HER2-Positive Early Breast Cancer in the Netherlands
36. Modeling Complex Treatment Strategies: Construction and Validation of a Discrete Event Simulation Model for Glaucoma
37. The cost-effectiveness of particle therapy in non-small cell lung cancer: Exploring decision uncertainty and areas for future research
38. How costly is particle therapy? Cost analysis of external beam radiotherapy with carbon-ions, protons and photons
39. Consumer willingness to invest money and time for benefits of lifestyle behaviour change: an application of the contingent valuation method
40. The Impact of Structural Uncertainty on Cost-Effectiveness Models for Adjuvant Endocrine Breast Cancer Treatments: the Need for Disease-Specific Model Standardization and Improved Guidance
41. The Transferability of Economic Evaluations: Testing the Model of Welte
42. More is not always better: Cost-effectiveness analysis of combined, single behavioral and single physical rehabilitation programs for chronic low back pain
43. Acknowledging Patient Heterogeneity in Economic Evaluation: A Systematic Literature Review
44. Lost Productivity in Four European Countries among Patients with Rheumatic Disorders: Are Absenteeism and Presenteeism Transferable?
45. Methodological Quality of Economic Evaluations of New Pharmaceuticals in the Netherlands
46. Observational studies: a valuable source for data on the true value of RA therapies
47. The burden of illness of rheumatoid arthritis
48. MRI with a lymph-node-specific contrast agent as an alternative to CT scan and lymph-node dissection in patients with prostate cancer: a prospective multicohort study
49. Difficulties in Calculating Productivity Costs: Work Disability Associated with Borderline Personality Disorder
50. The long term effectiveness and cost-effectiveness of initiating treatment for ocular hypertension
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.